Qnovia, a Richmond, VA-based pharmaceutical company, raised $16M in Series B funding.
The round was led by Blue Ledge Capital, Evolution VC Partners, Vice Ventures and Gaingels.
The company intends to use the funds to support the clinical, regulatory, and commercial development of its lead asset, RespiRx™ Nicotine Inhaler (QN-01) in the UK, and to evaluate the feasibility of additional therapeutic indications in their pipeline.
Founded by Mario Danek in 2018, Qnovia is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. Its drug delivery platform, the RespiRx™, is an orientation-agnostic, portable vibrating mesh nebulizer that effectively operates in any position held by the patient. It sees opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs.
The company has raised $50m since its inception.
FinSMEs
10/12/2024